The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Seed VC | Alive

Total Raised


Last Raised

$4.56M | 4 yrs ago

About Synthomics

Developer of instrumentation for gene synthesis analysis. The company develops a DNA and RNA synthesizer for molecular biology research purposes. The platform aims to deliver less expensive, higher quality, reduced turn-around-time oligonucleotide synthesis solutions.

Synthomics Headquarter Location

3477 Edison Way

Menlo Park, California, 94025,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Synthomics Patents

Synthomics has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Fluid dynamics
  • Genetics
patents chart

Application Date

Grant Date


Related Topics



Biotechnology, Molecular biology, Fluid dynamics, Genetics, Genomics


Application Date


Grant Date


Related Topics

Biotechnology, Molecular biology, Fluid dynamics, Genetics, Genomics



  • Where is Synthomics's headquarters?

    Synthomics's headquarters is located at 3477 Edison Way, Menlo Park.

  • What is Synthomics's latest funding round?

    Synthomics's latest funding round is Seed VC.

  • How much did Synthomics raise?

    Synthomics raised a total of $5.69M.

  • Who are the investors of Synthomics?

    Investors of Synthomics include True Ventures, Genoa Ventures and National Institutes of Health.

  • Who are Synthomics's competitors?

    Competitors of Synthomics include Catalog Technologies.

You May Also Like

Kilobaser Logo

KioBaser is building what it dubs "Nespresso machine of DNA synthesis". The machine creates DNA primers, a short single strand of RNA or DNA (generally about 18-22 bases) that serves as a starting point for DNA synthesis.

DNA Script Logo
DNA Script

DNA Script is a biotech start-up that manufactures de novo synthetic nucleic acids using an enzymatic technology. The company aims to introduce a biochemical process for DNA and RNA synthesis based on the use of efficient enzymes. This technology mimics the way nature produces genetic code and enables enhanced performance while minimizing the use of harsh chemicals.

Evonetix Logo

Evonetix develops a desktop, short-latency solution to synthesize DNA to facilitate the field of synthetic biology, with application across industries including healthcare, pharma, biotech, food and agriculture and data storage.

Molecular Assemblies Logo
Molecular Assemblies

Molecular Assemblies develops an enzymatic DNA synthesis technology designed to power DNA-based products. Enzymatic DNA synthesis can write long, pure DNA, which is required to free the potential of synthetic biology applications, such as personalized medicines (including CAR-T cell therapies and CRISPR gene editing) and advanced agricultural and industrial products, through gene development and DNA-based data storage.

Helixworks Technologies

Helixworks Technologies is a biotechnology company specializing in DNA synthesis.


Iridia is developing a DNA-based data storage solution. By combining DNA polymer synthesis technology, electronic nano-switches and semiconductor fabrication technologies, Iridia is developing a highly-parallel format to enable an array of nanomodules with the potential to store data at exceptionally high density.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.